{"id":"NCT02849080","sponsor":"Novo Nordisk A/S","briefTitle":"Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.","officialTitle":"Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-20","primaryCompletion":"2018-02-28","completion":"2019-03-27","firstPosted":"2016-07-29","resultsPosted":"2020-02-17","lastUpdate":"2022-07-20"},"enrollment":504,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"semaglutide","otherNames":[]},{"type":"DRUG","name":"sitagliptin","otherNames":[]}],"arms":[{"label":"Semaglutide flexible dosing (3, 7 or 14 mg)","type":"EXPERIMENTAL"},{"label":"Sitagliptin 100 mg","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is globally conducted. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus.","primaryOutcome":{"measure":"Participants Who Achieve HbA1c <7.0% (53 mmol/Mol) ADA Target (Yes/no)","timeFrame":"Week 52","effectByArm":[{"arm":"Oral Semaglutide Flex- Main Phase","deltaMin":134,"sd":null},{"arm":"Sitagliptin 100 mg- Main Phase","deltaMin":60,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":83,"countries":["United States","Argentina","Austria","Belgium","Brazil","Egypt","Norway","South Korea","Switzerland","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["31189520","33318068","35373893","33660198","32998732","32267058","31903692"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":253},"commonTop":["Nausea","Nasopharyngitis","Headache","Diarrhoea","Upper respiratory tract infection"]}}